The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Phase 3 Recruiting
500 enrolled
TB06
Phase 3 Recruiting
100 enrolled
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 Recruiting
1,000 enrolled
OPERA-02
Phase 3 Recruiting
1,000 enrolled
NoLEEta
Phase 3 Recruiting
3,902 enrolled
OPERA-01
Phase 3 Recruiting
510 enrolled
MK-2870-010
Phase 3 Recruiting
1,200 enrolled
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
Phase 3 Recruiting
258 enrolled
INAVO123
Phase 3 Recruiting
450 enrolled
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 3 Recruiting
920 enrolled
DEBRA
Phase 3 Recruiting
1,670 enrolled
OFSET
Phase 3 Recruiting
3,960 enrolled
HEAL-ABC
Phase 3 Recruiting
402 enrolled
ReDiscover-2
Phase 3 Recruiting
540 enrolled
Adjuvant WIDER
Phase 3 Recruiting
1,400 enrolled
FourLight-3
Phase 3 Recruiting
1,020 enrolled
CAPIcorn
Phase 3 Recruiting
250 enrolled
POWER II
Phase 3 Recruiting
354 enrolled
OLIGAMI
Phase 3 Recruiting
340 enrolled
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Phase 3 Recruiting
250 enrolled
OFOBA
Phase 3 Recruiting
158 enrolled
ELAINEIII
Phase 3 Recruiting
500 enrolled
CHORD
Phase 3 Recruiting
182 enrolled
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Phase 3 Recruiting
1,903 enrolled
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Phase 3 Recruiting
269 enrolled
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Phase 3 Recruiting
115 enrolled
TAILOR RT
Phase 3 Recruiting
2,140 enrolled
CAPItrue
Phase 3 Recruiting
300 enrolled
BRIA-ABC
Phase 3 Recruiting
404 enrolled
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Phase 3 Recruiting
312 enrolled
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
Phase 3 Recruiting
126 enrolled
ECLECTIC
Phase 3 Recruiting
300 enrolled
Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer
Phase 3 Recruiting
388 enrolled
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Phase 3 Recruiting
430 enrolled
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Phase 3 Recruiting
192 enrolled
LOLIPOP
Phase 3 Recruiting
4,300 enrolled
HOPE
Phase 3 Recruiting
180 enrolled
ADAPT-TN-III
Phase 3 Recruiting
348 enrolled
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
Phase 3 Recruiting
1,602 enrolled
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
Phase 3 Recruiting
285 enrolled
CAPS5
Phase 3 Recruiting
9,000 enrolled
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Phase 3 Recruiting
491 enrolled
FLAMINGO-01
Phase 3 Recruiting
750 enrolled
Med-RT BG
Phase 3 Recruiting
34 enrolled
AURA
Phase 3 Recruiting
290 enrolled
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Phase 3 Recruiting
300 enrolled
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Phase 3 Recruiting
460 enrolled
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 Recruiting
256 enrolled
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3 Recruiting
400 enrolled
COMPRO
Phase 3 Recruiting
276 enrolled